Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m. ET in Boston, MA.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular TherapiesIntra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Contact:Intra-Cellular Therapies, Inc.Juan Sanchez, M.D.Vice President, Corporate Communications and Investor Relations646-440-9333

Burns McClellan, Inc.Cameron Radinovic cradinovic@burnsmc.com 646-930-4406

Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Intra Cellular Therapies Charts.
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Intra Cellular Therapies Charts.